Cherwell Laboratories, specialists in products for environmental monitoring and process validation are pleased to announce the appointment of Abdulmajeed Raji (Ph.D Microbiology) as Microbiology Product Specialist. Abdul has had many ...
Tags: Industrial Microbiology Expertise, environmental monitoring
Galapagos has reached a milestone in its immuno-inflammation alliance with GlaxoSmithKline (GSK) by delivering a fifth pre-clinical drug candidate. Galapagos CEO Onno van de Stolpe said the company has identified five candidate drugs of ...
Tags: immuno inflammation, GSK, clinical drug, drug
Priaxon has signed research collaboration with GlaxoSmithKline (GSK) to develop small molecule modulators for various protein-protein-interactions (PPIs). The collaboration will utilize Priaxon's small molecule drug discovery knowledge in ...
Tags: Priaxon, GSK, drug discovery, clinical development, therapeutic areas
Snap Fashion has beaten 300 UK companies to win first place in Cisco's BIG Awards 2012. Snap fashion was crowned winner at Cisco House, during an awards ceremony which also saw companies Digital Shadows and Six3 come second and third ...
Tags: Snap Fashion, Cisco BIG Awards, app, Digital Shadows
GlycoVaxyn and GlaxoSmithKline Biologicals(GSK)have signed a research partnership for the development of new bacterial vaccines. The collaboration,planned for three years,will leverage GlycoVaxyn's bio-conjugation technology in developing ...
Tags: GSK, Glycovaxyn, bacterial vaccines, Partnership
GlaxoSmithKline (GSK) and Theravance have submitted a regulatory application in the US for the investigational once-daily LAMA/LABA combination medicine, umeclidinium bromide (UMEC/VI), to treat chronic obstructive pulmonary disease (COPD) ...
Tags: GlaxoSmithKline, regulatory application, Medicine, FDA
NeRRe Therapeutics is established as a new drug discovery company for the development of a range of clinical and pre-clinical neurokinin antagonists separated from GlaxoSmithKline(GSK). The company,based at Stevenage Bioscience ...
Tags: NeRRe Therapeutics, GSK, pre-clinical neurokinin antagonists
GlaxoSmithKline (GSK) has announced the FDA approval of four-strain seasonal influenza (flu) virus vaccine, Fluarix Quadrivalent, to immunize adults and children of three years age and more, in the US. The intramuscular vaccine is ...
GlaxoSmithKline (GSK) has announced FDA approval of raxibacumab anti-toxin as a combination therapy along with antibacterial drugs for the treatment of inhalational anthrax in both adult and pediatric patients with limited treatment ...
GlaxoSmithKline has launched a new program to reduce the environmental impact of GSK respiratory inhalers sent to landfills. The program, Complete the Cycle Recycle, is designed to help people to deposit their empty inhalers at ...
Tags: GlaxoSmithKline, GSK, program, GSK respiratory
Isis Pharmaceuticals has obtained the US FDA fast track designation for ISIS-TTR to treat familial amyloid polyneuropathy (FAP). The antisense drug ISIS-TTR, a part of the Isis-GSK strategic RNA therapeutic alliance, is being developed ...
Tags: amyloid polyneuropathy candidate, Pharmaceuticals, genetic disease, drug
GlaxoSmithKline (GSK), Ligand Pharmaceuticals' partner, has gained FDA priority review status for the supplemental new drug application for Promacta to treat thrombocytopenia in adult patients with chronic hepatitis C virus infection. ...
Tags: GlaxoSmithKline, GSK, promacta, thrombocytopenia
GlaxoSmithKline (GSK) and XenoPort have gained FDA approval for Horizant (gabapentin enacarbil) extended-release tablets for postherpetic neuralgia (PHN). A single 12-week principal efficacy trial and two supportive studies that met their ...
GlaxoSmithKline (GSK) has received FDA approval for Votrient (pazopanib) for the treatment of patients with advanced soft tissue sarcoma (STS) who have received prior chemotherapy. The approval is based on the results of the randomized, ...
Tags: advanced soft tissue sarcoma, STS, soft tissue sarcomas, GlaxoSmithKline
Research-based pharmaceutical and healthcare company GlaxoSmithKline (GSK) has completed acquisition of Human Genome Sciences (HGS) for $3.6bn on an equity basis, or approximately $3 billion net of cash and debt. With the acquisition, all ...
Tags: GSK, GlaxoSmithKline, Human Genome Sciences